Pre-Operative Or Peri-Operative Dox Regimen In Patients With Locally Advanced Resectable Gastric Cancer (GastroDOC)
A Randomised Phase Ii Study Of Pre-Operative Or Peri-Operative Docetaxel, Oxaliplatin, Capecitabine (Dox) Regimen In Patients With Locally Advanced Resectable Gastric Cancer
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
A PHASE2 clinical study on Gastric Cancer and Locally Advanced Malignant Neoplasm, this trial is completed. The trial is conducted by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS and has accumulated 9 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Apr 2025 — Sep 2025 [monthly]
Completed PHASE2
-
Feb 2025 — Apr 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Jan 2017 — Aug 2017 [monthly]
Recruiting PHASE2
First recorded
Sep 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ancona, Italy , Bibbiena, Italy , Brescia, Italy , Cesena, Italy , Empoli, Italy , Florence, Italy , Meldola (FC), Italy , Milan, Italy , Montevarchi, Italy , Pavia, Italy and 10 more locations